These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1968541)

  • 1. Antistreptokinase titres after intravenous streptokinase.
    Lancet; 1990 Mar; 335(8688):534. PubMed ID: 1968541
    [No Abstract]   [Full Text] [Related]  

  • 2. Antistreptokinase titres after intravenous streptokinase.
    Jalihal S; Morris GK
    Lancet; 1990 Jan; 335(8683):184-5. PubMed ID: 1967665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres.
    Lee HS; Yule S; McKenzie A; Cross S; Reid T; Davidson R; Jennings K
    Eur Heart J; 1993 Dec; 14(12):1640-3. PubMed ID: 8131761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.
    Fears R; Ferres H; Glasgow E; Standring R; Hogg KJ; Gemmill JD; Burns JM; Rae AP; Dunn FG; Hillis WS
    Br Heart J; 1992 Aug; 68(2):167-70. PubMed ID: 1389731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should streptokinase be readministered? Insights from recent studies of antistreptokinase antibodies.
    Cross DB
    Med J Aust; 1994 Jul; 161(2):100-1. PubMed ID: 8028530
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions.
    Laisaar T; Pullerits T
    Chest; 2003 Feb; 123(2):432-5. PubMed ID: 12576362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antistreptokinase antibodies following a dose of streptokinase.
    Chesser SL; Mauro VF
    Ann Pharmacother; 1994 Feb; 28(2):204-6. PubMed ID: 8173136
    [No Abstract]   [Full Text] [Related]  

  • 9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase.
    Lee HS; Cross S; Davidson R; Reid T; Jennings K
    Eur Heart J; 1993 Jan; 14(1):84-9. PubMed ID: 8432298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.
    Naylor CD; Armstrong PW
    CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction.
    Rosenschein U; Lenz R; Radnay J; Ben Tovim T; Rozenszajn LA
    Isr J Med Sci; 1991 Oct; 27(10):541-5. PubMed ID: 1955306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptokinase resistance: when might streptokinase administration be ineffective?
    Buchalter MB; Suntharalingam G; Jennings I; Hart C; Luddington RJ; Chakraverty R; Jacobson SK; Weissberg PL; Baglin TP
    Br Heart J; 1992 Nov; 68(5):449-53. PubMed ID: 1467027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tissue plasminogen activator is the best thrombolytic agent].
    Bates E
    Arq Bras Cardiol; 1994 Jul; 63(1):57-8. PubMed ID: 7857215
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should intravenous thrombolytic agents for acute myocardial infarction be selected?
    Topol EJ
    Cardiovasc Clin; 1990; 21(1):57-75; discussion 76-8. PubMed ID: 2143103
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intravenous thrombolytic therapy in acute infarct of the myocardium].
    Núñez P; Motta J; Arrocha A; Soto V
    Rev Med Panama; 1989 Jan; 14(1):16-25. PubMed ID: 2499016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombolytic therapy of acute myocardial infarction].
    Chen JL
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):69-70. PubMed ID: 15808085
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombolytic therapy in acute myocardial infarction.
    Smucker DR; Burket MW
    Am Fam Physician; 1988 May; 37(5):265-74. PubMed ID: 3129924
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.